Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Abstract Text:

Polyethylene glycol (PEG)-diacyl lipid micelles have been prepared by loading with the hydrophobic meso-5,10,15,20-tetraphenyl-21H,23H-porphine (TPP) and used for the photodynamic treatment of B-16 melanoma cells in vitro and in vivo. The use of PEG-PE micelles allowed for a 150-fold increased the solubilization of TPP, compared with the native drug. The average size of the PEG-PE micelles was in the range of 10-12 nm with a narrow size distribution. At 50 mug/ml of TPP in micelles with an irradiation intensity of 4.5-21.5 mW/cm(2), the viability of B-16 melanoma cells in vitro decreased in a fluence-dependent manner. A highly effective outcome of photodynamic therapy (PDT) with TPP-loaded PEG-PE micelles can be further increased by modifying such micelles with cancer-specific monoclonal antibody 2C5 to TPP-loaded micelles to tumor cells. TPP-containing 2C5-modified micelles provided the strongest phototoxic effect against B-16 cells in vitro compared with TPP-loaded plain micelles at the same TPP concentration. The association of TPP-loaded immuno-targeted micelles with melanoma cells was also studied by flow cytometry. An increase in cell association was found for 2C5-targeted micelles compared with non-targeted micelles. In vivo, the PDT treatment of subcutaneous melanoma-bearing C57BL/6 mice with 100 mW/cm(2) of 630 nm laser light 9 h after the administration of the micellar TPP (1 mg/kg of TPP) resulted in a significant inhibition of tumor growth. Compared with controls, the weight of postmortem tumors was approx. 3.5- and 7.5-fold smaller with TPP-loaded PEG-PE micelles and TPP-loaded PEG-PE 2C5-immunomicelles, respectively.

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of drug targeting

VOLUME: 16

Page Numbers: 486-93

Journal Abbreviation:

ISSN: 1061-186X

DAY: 8

MONTH: Jul

YEAR: 2008

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9312476

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.

AFFILIATION: Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, MA, USA.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Drug Target

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles Related Publications

• "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
• "Smart" Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes.
• Antibody-modified liposomes for cancer chemotherapy.
• Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
• Bioengineering and Imaging Research Opportunities Workshop V: A summary on Imaging and Characterizing Structure and Function in Native and Engineered Tissues.
• Bioengineering and Imaging Research Opportunities Workshop V: a white paper on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop V: summary of findings on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop v: a summary.
• Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates.
• Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
• Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
• Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
• Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes.
• Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy.
• Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity.
• Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
• Nanocarriers.
• PEGylated dextran as long-circulating pharmaceutical carrier.
• Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.
• Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux.
• Polymeric contrast agents for medical imaging.
• Preface. Fifth International Nanomedicine and Drug Delivery Symposium (NanoDDS'07).
• Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction.
• Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology.
• Surface Modification of Pharmaceutical Nanocarriers with Ascorbate Residues Improves their Tumor-Cell Association and Killing and the Cytotoxic Action of Encapsulated Paclitaxel In Vitro.
• TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice.
• Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers.
• Tatp-mediated intracellular delivery of pharmaceutical nanocarriers.
• The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells.
• Tumor-specific antibody-mediated targeted delivery of Doxil((R)) reduces the manifestation of auricular erythema side effect in mice.